Truist Securities Maintains Buy on Sabra Health Care REIT, Raises Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained its Buy rating on Sabra Health Care REIT (NASDAQ:SBRA) and raised the price target from $15 to $16, as per analyst Michael Lewis.
June 27, 2024 | 12:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has maintained its Buy rating on Sabra Health Care REIT and raised the price target from $15 to $16, indicating confidence in the company's future performance.
The raised price target and maintained Buy rating from Truist Securities suggest positive sentiment and confidence in Sabra Health Care REIT's future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100